Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) has been granted intellectual property protection for its dimethyltryptamine-containing drugs.
On Wednesday, the United Kingdom-based biotechnology company announced news of a second United States patent for its psychedelic portfolio.
The patent will offer therapeutic composition protection for a small group of deuterated DMT compounds that will have an expected “lifetime of exclusivity” lasting until April 2041. The company now has a total of 12 patents for its psychedelic and non-psychedelic drug catalogue.
Read more: Psychedelic drugs market awaits nearly 100% revenue expansion by 2026 end: Fairfield
Read more: European Psychiatric Association aligns with PAREA: a multi-organization psychedelic partnership
“We have made significant strides this year progressing our research and development programs and in securing key IP to support and protect them. We secured eight patent grants so far this year, bringing our total from four to twelve,” said George Tziras, CEO of Small Pharma.
“The grant of this second United States patent effectively protects all pharmaceutical formulations of the specified deuterated DMT compounds, enabling us to progress our deuterated pipeline with even greater confidence.”
Small Pharma is a company that is primarily focused on the development of a series of short-acting psychedelic-assisted therapies intended to treat mental health conditions, particularly depression. The biotech organization is currently in the midst of progressing a synthetic formulation of DMT designated as SPL026 that will be administered via intravenous for the treatment of major depressive disorder (MDD).
“Psychedelic medicines provide us with an exquisite opportunity to bring together neuroscience, psychiatry and psychotherapy to treat mental illness. They may become medicines that help to free us from the avalanche of psychological suffering affecting our societies,” said Graham Campbell, a psychiatrist working on Small Pharma’s clinical trials.
Small Pharma emphasizes the importance of responsible psychedelic-assisted therapy and believes in the value of safe, diligent and efficacious clinical practices.
